A new combination of smart drugs can destroy the deadliest form of skin cancer – even if it is diagnosed at a late stage, a new study shows.
The study has suggested that a cocktail of two existing immunotherapy drugs may both prolong patients lives and destroy all traces of melanoma in one in five patients’. The results have been described as very promising.
The combination of drugs given was ipilimumab and nivolumab. The study showed 69% of patients given the combination still alive two years later compared to 53% who were given ipilimumab alone, Sky News reported.
Dr James Larkin an oncologist at The Royal Marsden Hospital, said: “Combining these two immunotherapies is an effective two-pronged attack against the cancer.”
The findings were revealed at the annual meeting of the American Association for Cancer Research.
The combination is yet to be approved in the UK, but both are individually so there is great hope they will be available together in the near future.